SignatureFD’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$48.5K Buy
344
+22
+7% +$3.14K ﹤0.01% 1976
2026
Q2
$39.5K Buy
322
+34
+12% +$3.55K ﹤0.01% 2011
2026
Q1
$30.4K Buy
288
+125
+77% +$11.1K ﹤0.01% 2008
2025
Q4
$14.2K Buy
163
+14
+9% +$1.15K ﹤0.01% 2262
2025
Q3
$9.9K Hold
149
– – ﹤0.01% 2408
2025
Q2
$8.24K Buy
149
+55
+59% +$2.64K ﹤0.01% 2420
2025
Q1
$4.55K Buy
+94
New +$3.94K ﹤0.01% 2638
2024
Q4
– Sell
-20
Closed -$900 – 3379
2024
Q3
$900 Buy
+20
New +$808 ﹤0.01% 3018
2023
Q3
– Sell
-33
Closed -$911 – 3282
2023
Q2
$911 Buy
+33
New +$826 ﹤0.01% 2992
2022
Q2
– Sell
-78
Closed -$2K – 3298
2022
Q1
$2K Buy
78
+32
+70% +$902 ﹤0.01% 2840
2021
Q4
$2K Hold
46
– – ﹤0.01% 2778
2021
Q3
$1K Hold
46
– – ﹤0.01% 2894
2021
Q2
$2K Hold
46
– – ﹤0.01% 2610
2021
Q1
$1K Hold
46
– – ﹤0.01% 2666
2020
Q4
$1K Hold
46
– – ﹤0.01% 2471
2020
Q3
$1K Buy
+46
New +$863 ﹤0.01% 2477

Other funds holding PTGX

SignatureFD's PTGX Position: Q3 2026 in Review

SignatureFD increased its Protagonist Therapeutics (PTGX) stake by 6.8% in Q3 2026, buying an estimated $3.14K and bringing the position to 344 shares worth $48.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

SignatureFD first reported a position in PTGX in Q3 2020 and has held it in 16 quarters since. 379 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • SignatureFD held 344 shares of Protagonist Therapeutics worth $48.5K as of Q3 2026.
  • SignatureFD bought 22 Protagonist Therapeutics shares in Q3 2026, an estimated $3.14K.
  • Protagonist Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #1976 holding.
  • SignatureFD first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 16 quarters since.
  • 379 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.